Previous close | 19.46 |
Open | 19.74 |
Bid | 19.16 x 0 |
Ask | 19.30 x 0 |
Day's range | 19.14 - 19.76 |
52-week range | 8.44 - 20.25 |
Volume | |
Avg. volume | 18,737 |
Market cap | 669.7M |
Beta (5Y monthly) | 0.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.73 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 50.00 |
Election of the board of directors and auditor
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform.
On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 (ISIN SE0015193958) (the "Existing Bonds").